U.S. markets close in 2 hours 48 minutes

NeuBase Therapeutics, Inc. (NBSE)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8033-0.0665 (-7.65%)
As of 12:49PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close0.8698
Bid0.7900 x 1000
Ask0.8190 x 800
Day's Range0.7699 - 0.8380
52 Week Range0.6050 - 8.5340
Avg. Volume2,399,473
Market Cap2.996M
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)-20.2900
Earnings DateDec 19, 2023 - Dec 26, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est140.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for NBSE

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • NeuBase Therapeutics, Inc.
    Technical Assessment: Neutral in the Intermediate-TermAt the lows this week, the S&P 500 (SPX) fell right to the bottom of its bullish channel that started in October. In addition, the index hit the lower part of its very short-term channel off its late-July highs. With the market oversold and at support, it would not be surprising to see a counter-trend rally, but we are leaning toward a failed rally and then another leg lower.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    NeuBase Therapeutics Issues Statement Regarding Filing By Shareholder

    PITTSBURGH, Sept. 08, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”) today issued the following statement regarding the Schedule 13D filed with the U.S. Securities and Exchange Commission on August 31, 2023, by Symetryx Corporation (“Symetryx”) and their subsequent press release issued on September 6, 2023. “The NeuBase Board of Directors (“Board”) appreciates input from its shareholders. The Board remains committed to completing its comprehensive

  • PR Newswire


    Today, Symetryx Corporation ("Symetryx") announced that it has acquired 20% of the issued and outstanding common stock in Neubase Therapeutics Inc. (NASDAQ: NBSE) ("Neubase"). Symetryx is now urging the Board to issue a special $1 per share dividend.

  • GlobeNewswire

    NeuBase Therapeutics to Explore Strategic Alternatives

    PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced that its Board of Directors (the “Board”) has completed a review of the Company’s business, including the status of its programs, resources, and capabilities. The Board has made the determination to halt further development of the Company’s pro